Supports appetite control and reduces food cravings
Slows gastric emptying
Enhances insulin production and improves blood sugar regulation
May reduce body weight and body fat percentage
Tirzepatide is an FDA-approved, once-weekly injectable medication used for type 2 diabetes management and chronic weight management. It is a dual agonist, mimicking two gut hormones—GIP and GLP-1—to improve blood sugar control, reduce appetite, and slow digestion, often leading to significant weight loss.
It is the first dual receptor agonist targeting both Glucose-dependent Insulinotropic Polypeptide (GIP) and Glucagon-like Peptide-1 (GLP-1) receptors. This combined action typically results in more effective blood sugar regulation and weight loss than traditional single-action GLP-1 medications like semaglutide.
Improves glycemic control by stimulating insulin secretion and decreasing glucagon, which helps lower blood sugar levels.
It is approved to treat moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity.
GLP-1
Glips
There are no long-term human studies, and these peptides are not approved by the FDA, with potential risks unknown.
They are often sourced through specialized, clinician-guided, or anti-aging, clinics.
